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Abstract 
Current treatment of autoimmune disease usually involves the use of cytotoxic drugs or biologic 
agents that interfere with the activity of B cells, T cells or key cytokines, such as TNF, IL-1 and 
IL-6. On occasion, polyclonal immunoglobulin G (IgG), intravenous (IVIg) is used. The discovery 
of IgG- (and hence IVIg-) derived T regulatory (Treg) epitopes that trigger the expansion of 
Tregs in vitro and in vivo provides a novel explanation for the effect of IVIg. These IgG-derived 
Treg epitopes (also known as Tregitopes) appear to be effective on their own (in vivo, in 
autoimmune disease models) and when co-administered with a specific autoimmune disease 
antigen, contribute to antigen-specific tolerance induction. A description of Tregitopes and a 
brief discussion of their potential applications in autoimmune disease are provided here. 
Tregitope-based immunotherapy has the potential to modify the current autoimmune 
pharmacopeia. 
 
Tregitopes are regulatory T-cell epitope sequences contained in IgG that were 
discovered by the team of De Groot and Martin in the course of searching for T effector (Teff) 
epitopes in monoclonal antibody (mAb) therapeutics [1,2]. These highly conserved (in IgG), 
promiscuous Treg epitopes have been shown to trigger the expansion of Tregs in vitro. A 
retrospective review of the T-cell epitope (and Tregitope) content of therapeutic mAbs, 
published in 2009 [3], revealed a close correlation between the presence of Tregitopes and the 
absence of HLAbinding Teff epitopes, with the lack of mAb immunogenicity in clinical use. 
Taking this observation one step further, the presence of Treg epitopes in IgG might 
explain why immunoglobulins, which are produced by B cells that undergo somatic 
hypermutation in the periphery, do not generally elicit the expected immune response against 
the new ‘foreign’ hypervariable (complementarity determining regions, or CDR) sequences. 
Recognition of the importance of Tregitopes in mAb therapeutics led to the incorporation of 
Tregitope specific adjustments in certain immunogenicity predictions, improving the accuracy of 
the results [4,5]. 
 Tregitopes may also explain, in part, the tolerance-inducing effect of intravenous 
immunoglobulin (IVIg) therapy [6]. This theory is supported by reports that IVIg-induced 
expansion of Tregs in vitro and in vivo, [7–9], and IVIg experts generally agree that Treg 
epitopes such as Tregitopes may be contributing to the tolerizing effects of IVIg [10,11]. 
Although it is only approved for use in a handful of diseases [12], IVIg is used off-label for 
hundreds of conditions [13–19]. 
Recently published in vivo studies of Tregitopes in mouse models of human autoimmune 
diseases have further validated the Tregitope discovery [20]. Additional publications 
demonstrate that co-administration of Tregitopes with target antigens in vivo and in vitro leads to 
the induction of antigen-specific tolerance [2,21] and suppression of both humoral [22] and 
cellular immune responses, including antigen-specific CD8+ T-cell response [6,23]. ‘Control’ 
peptides have been compared in vitro and in vivo [24] and have not been shown to have the 
same effect. In another recent publication, cross-conservation (at the T-cell receptor surface) 
with other highly conserved T-cell epitopes in autologous proteins is identified as a potential 
distinguishing feature of Treg epitopes (such as Tregitopes) but not from Teff epitopes [25]. 
Other groups have reported that specific IgG-derived peptides subsequently identified as 
Tregitopes [26–28] induce tolerance in animal and human autoimmune disease, providing 
independent confirmation of Tregitope studies. 
The proposed Tregitope mechanism of action is distinct from some IVIg mechanisms of 
action but similar to others (FIGURE 1). For example, Tregitopes are unlikely to be involved in 
the induction of tolerance by the formation of immune complexes, blockade of Fc receptors and 
thereby clearance of anti-self-antibodies; immuno-modulation via antiidiotypic interactions, 
inhibition of complement-mediated tissue damage and inhibition of superantigen-mediated T-cell 
activation; but may be involved in tolerance induction following interaction of sialylated Fc with 
DC-SIGN, and in direct modulation of cytokine expression (by Tregs); as well as induction of 
Tregs [13]. IVIg has also recently been shown to be associated with modulation of the 
regulatory T-cell axis, reduction of IL-17 and enhancement of the suppressive function of Tregs. 
Many of these effects can be explained by uptake of Tregitope by antigen-presenting cells, 
processing and presentation of Tregitopes to T cells, which respond by inducing Tregs to be 
activated and express FoxP3 and CD25. IgG processing and epitope presentation is likely to 
occur when the IgG recycling protein, FcRN, is overwhelmed (as it may be when high doses of 
IgG, as in IVIg, are given). 
The discovery of Tregitopes naturally led to the concept of actively integrating Tregitopes 
into biologics. Tolerization of immune responses to protein therapeutics (by introduction of 
Tregitopes) could be considered to be an alternative to humanization of mAbs, and it might also 
be applied to non-mAb biologic products [20]. Tolerization across the breadth of HLA alleles 
expressed in the general human population would involve inclusion of the complete repertoire of 
Tregitopes present in each IgG that is developed for clinical applications. Studies that support 
the effectiveness of this approach have been carried out by De Groot and Cousens et al. 
[6,20,21] and are currently underway in the laboratories of a number of other research groups 
[22,23]. 
The origin of Tregitope-specific T cells is as yet undetermined. They may be natural 
Tregs, induced Tregs or both. Regardless of the origin or mechanism of action of Tregitopes, 
the potential for these peptides to alter the course of autoimmune diseases as a replacement for 
cytotoxic therapy, or as an alternative to biological disease modifiers, is certainly worth 
consideration. Albumin has been proposed as a carrier for Tregitopes, since albumin itself may 
contain Tregitopes, and it has been used with a wide range of therapeutic proteins as a stable 
and non-immunogenic excipient. 
Tregitopes may also be useful for their IVIg-like effects in conditions such as allergy, 
where Treg induction is considered to be important but IVIg was considered to be too 
dangerous (and expensive) to use as therapy. Tregitopes could be combined with the target of 
autoimmunity, where the target is known, such as glutamic acid decarboxylase (GAD 65) 
protein in diabetes. For example, early studies in autoimmune disease models clearly 
demonstrate that Tregitopes have promise as a standalone treatment for autoimmune disease 
[6,20]. Where the antigen is unknown, Tregitope immunotherapy might be given during a flare, 
when autoimmune antigens are being presented to the immune system by activated antigen-
presenting cells. Whether used on their own, or co administered with a specific autoimmune 
disease antigen, Tregitope-based immunotherapy has the potential to augment future 
therapeutic options for autoimmune disease. 
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